Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102

Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J. Stella, Brian Burnette, Melinda Telli, Della F. Makower, Puneet Cheema, Cristina I. Truica, Antonio C. Wolff, Gamini S. Soori, Barbara Haley, Timothy R. Wassenaar, Lori J. Goldstein, Kathy D. Miller, Joseph A. Sparano

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102'. Together they form a unique fingerprint.

Medicine & Life Sciences